Discovery of GS-9131: Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148

Richard L. Mackman, Adrian S. Ray, Hon C. Hui, Lijun Zhang, Gabriel Birkus, Constantine G. Boojamra, Manoj C. Desai, Janet Douglas, Ying Gao, Deborah Grant, Genevieve Laflamme, Kuei Ying Lin, David Y. Markevitch, Ruchika Mishra, Martin McDermott, Rowchanak Pakdaman, Oleg V. Petrakovsky, Jennifer E. Vela, Tomas Cihlar

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

GS-9148 [(5-(6-amino-purin-9-yl)-4-fluoro-2,5-dihydro-furan-2-yloxymethyl)phosph onic acid] 4 is a novel nucleoside phosphonate HIV-1 reverse transcriptase (RT) inhibitor with a unique resistance profile toward N(t)RTI resistance mutations. To effectively deliver 4 and its active phosphorylated metabolite 15 into target cells, a series of amidate prodrugs were designed as substrates of cathepsin A, an intracellular lysosomal carboxypeptidase highly expressed in peripheral blood mononuclear cells (PBMCs). The ethylalaninyl phosphonamidate prodrug 5 (GS-9131) demonstrated favorable cathepsin A substrate properties, in addition to favorable in vitro intestinal and hepatic stabilities. Following oral dosing (3 mg/kg) in Beagle dogs, high levels (>9.0 μM) of active metabolite 15 were observed in PBMCs, validating the prodrug design process and leading to the nomination of 5 as a clinical candidate.

Original languageEnglish (US)
Pages (from-to)3606-3617
Number of pages12
JournalBioorganic and Medicinal Chemistry
Volume18
Issue number10
DOIs
StatePublished - May 15 2010
Externally publishedYes

Fingerprint

HIV Reverse Transcriptase
Organophosphonates
Reverse Transcriptase Inhibitors
Prodrugs
Nucleosides
Cathepsin A
Metabolites
Blood Cells
Blood
Carboxypeptidases
Substrates
Dogs
Mutation
Acids
Liver
GS-9148
GS-9131

Keywords

  • Cathepsin A
  • HIV
  • Nucleosides
  • Phosphonates
  • Prodrugs
  • Reverse transcriptase

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry

Cite this

Discovery of GS-9131 : Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148. / Mackman, Richard L.; Ray, Adrian S.; Hui, Hon C.; Zhang, Lijun; Birkus, Gabriel; Boojamra, Constantine G.; Desai, Manoj C.; Douglas, Janet; Gao, Ying; Grant, Deborah; Laflamme, Genevieve; Lin, Kuei Ying; Markevitch, David Y.; Mishra, Ruchika; McDermott, Martin; Pakdaman, Rowchanak; Petrakovsky, Oleg V.; Vela, Jennifer E.; Cihlar, Tomas.

In: Bioorganic and Medicinal Chemistry, Vol. 18, No. 10, 15.05.2010, p. 3606-3617.

Research output: Contribution to journalArticle

Mackman, RL, Ray, AS, Hui, HC, Zhang, L, Birkus, G, Boojamra, CG, Desai, MC, Douglas, J, Gao, Y, Grant, D, Laflamme, G, Lin, KY, Markevitch, DY, Mishra, R, McDermott, M, Pakdaman, R, Petrakovsky, OV, Vela, JE & Cihlar, T 2010, 'Discovery of GS-9131: Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148', Bioorganic and Medicinal Chemistry, vol. 18, no. 10, pp. 3606-3617. https://doi.org/10.1016/j.bmc.2010.03.041
Mackman, Richard L. ; Ray, Adrian S. ; Hui, Hon C. ; Zhang, Lijun ; Birkus, Gabriel ; Boojamra, Constantine G. ; Desai, Manoj C. ; Douglas, Janet ; Gao, Ying ; Grant, Deborah ; Laflamme, Genevieve ; Lin, Kuei Ying ; Markevitch, David Y. ; Mishra, Ruchika ; McDermott, Martin ; Pakdaman, Rowchanak ; Petrakovsky, Oleg V. ; Vela, Jennifer E. ; Cihlar, Tomas. / Discovery of GS-9131 : Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148. In: Bioorganic and Medicinal Chemistry. 2010 ; Vol. 18, No. 10. pp. 3606-3617.
@article{88b8761faf3441ff97f8665caf39392f,
title = "Discovery of GS-9131: Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148",
abstract = "GS-9148 [(5-(6-amino-purin-9-yl)-4-fluoro-2,5-dihydro-furan-2-yloxymethyl)phosph onic acid] 4 is a novel nucleoside phosphonate HIV-1 reverse transcriptase (RT) inhibitor with a unique resistance profile toward N(t)RTI resistance mutations. To effectively deliver 4 and its active phosphorylated metabolite 15 into target cells, a series of amidate prodrugs were designed as substrates of cathepsin A, an intracellular lysosomal carboxypeptidase highly expressed in peripheral blood mononuclear cells (PBMCs). The ethylalaninyl phosphonamidate prodrug 5 (GS-9131) demonstrated favorable cathepsin A substrate properties, in addition to favorable in vitro intestinal and hepatic stabilities. Following oral dosing (3 mg/kg) in Beagle dogs, high levels (>9.0 μM) of active metabolite 15 were observed in PBMCs, validating the prodrug design process and leading to the nomination of 5 as a clinical candidate.",
keywords = "Cathepsin A, HIV, Nucleosides, Phosphonates, Prodrugs, Reverse transcriptase",
author = "Mackman, {Richard L.} and Ray, {Adrian S.} and Hui, {Hon C.} and Lijun Zhang and Gabriel Birkus and Boojamra, {Constantine G.} and Desai, {Manoj C.} and Janet Douglas and Ying Gao and Deborah Grant and Genevieve Laflamme and Lin, {Kuei Ying} and Markevitch, {David Y.} and Ruchika Mishra and Martin McDermott and Rowchanak Pakdaman and Petrakovsky, {Oleg V.} and Vela, {Jennifer E.} and Tomas Cihlar",
year = "2010",
month = "5",
day = "15",
doi = "10.1016/j.bmc.2010.03.041",
language = "English (US)",
volume = "18",
pages = "3606--3617",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - Discovery of GS-9131

T2 - Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148

AU - Mackman, Richard L.

AU - Ray, Adrian S.

AU - Hui, Hon C.

AU - Zhang, Lijun

AU - Birkus, Gabriel

AU - Boojamra, Constantine G.

AU - Desai, Manoj C.

AU - Douglas, Janet

AU - Gao, Ying

AU - Grant, Deborah

AU - Laflamme, Genevieve

AU - Lin, Kuei Ying

AU - Markevitch, David Y.

AU - Mishra, Ruchika

AU - McDermott, Martin

AU - Pakdaman, Rowchanak

AU - Petrakovsky, Oleg V.

AU - Vela, Jennifer E.

AU - Cihlar, Tomas

PY - 2010/5/15

Y1 - 2010/5/15

N2 - GS-9148 [(5-(6-amino-purin-9-yl)-4-fluoro-2,5-dihydro-furan-2-yloxymethyl)phosph onic acid] 4 is a novel nucleoside phosphonate HIV-1 reverse transcriptase (RT) inhibitor with a unique resistance profile toward N(t)RTI resistance mutations. To effectively deliver 4 and its active phosphorylated metabolite 15 into target cells, a series of amidate prodrugs were designed as substrates of cathepsin A, an intracellular lysosomal carboxypeptidase highly expressed in peripheral blood mononuclear cells (PBMCs). The ethylalaninyl phosphonamidate prodrug 5 (GS-9131) demonstrated favorable cathepsin A substrate properties, in addition to favorable in vitro intestinal and hepatic stabilities. Following oral dosing (3 mg/kg) in Beagle dogs, high levels (>9.0 μM) of active metabolite 15 were observed in PBMCs, validating the prodrug design process and leading to the nomination of 5 as a clinical candidate.

AB - GS-9148 [(5-(6-amino-purin-9-yl)-4-fluoro-2,5-dihydro-furan-2-yloxymethyl)phosph onic acid] 4 is a novel nucleoside phosphonate HIV-1 reverse transcriptase (RT) inhibitor with a unique resistance profile toward N(t)RTI resistance mutations. To effectively deliver 4 and its active phosphorylated metabolite 15 into target cells, a series of amidate prodrugs were designed as substrates of cathepsin A, an intracellular lysosomal carboxypeptidase highly expressed in peripheral blood mononuclear cells (PBMCs). The ethylalaninyl phosphonamidate prodrug 5 (GS-9131) demonstrated favorable cathepsin A substrate properties, in addition to favorable in vitro intestinal and hepatic stabilities. Following oral dosing (3 mg/kg) in Beagle dogs, high levels (>9.0 μM) of active metabolite 15 were observed in PBMCs, validating the prodrug design process and leading to the nomination of 5 as a clinical candidate.

KW - Cathepsin A

KW - HIV

KW - Nucleosides

KW - Phosphonates

KW - Prodrugs

KW - Reverse transcriptase

UR - http://www.scopus.com/inward/record.url?scp=77953325671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953325671&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2010.03.041

DO - 10.1016/j.bmc.2010.03.041

M3 - Article

C2 - 20409721

AN - SCOPUS:77953325671

VL - 18

SP - 3606

EP - 3617

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 10

ER -